SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.
Piper Jaffray & Co. and Jefferies & Company, Inc. are acting as joint book-running managers. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-managers for the offering.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402 or by fax at (612) 303-1070 and from Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY 10022 or by fax at (212) 284-2208.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Optimer Pharmaceuticals, Inc.
Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer currently has two late-stage anti-infective product candidates. Difimicin (OPT-80) is an antibiotic currently in a Phase 2b/3 registration trial for the treatment of Clostridium difficile-associated diarrhea, the most common hospital-acquired diarrhea. Prulifloxacin (OPT-99) is an antibiotic currently in a Phase 3 trial for the treatment of travelers’ diarrhea, a form of infectious diarrhea. The Company is developing additional product candidates using its proprietary technology, including its Optimer One-Pot Synthesis drug discovery platform.
Contact: Optimer Pharmaceuticals, Inc. John Prunty, Chief Financial Officer and Vice President Finance Christina Donaghy, Media Relations Specialist 858-909-0736 Fax: 858-909-0737 www.optimerpharma.com
Source: Optimer Pharmaceuticals, Inc.
